EUROPEAN COMMISSION

Brussels, 11.7.2025
C(2025) 4886 final

PUBLIC VERSION

Thermo Fisher Scientific Inc.
168 Third Avenue
Waltham, MA 02451
United States of America

Subject: **Case M.11959 – THERMO FISHER SCIENTIFIC / SOLVENTUM (PURIFICATION & FILTRATION BUSINESS)**
Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004 ([1]) and Article 57 of the Agreement on the European Economic Area ([2])

Dear Sir or Madam,

(1) On 16 June 2025, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation by which the undertaking Thermo Fisher Scientific Inc. ('Thermo Fisher', United States) will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of the Purification and Filtration Business of Solventum Corporation ('The Target', United States), controlled by Solventum Corporation (United States). The concentration is accomplished by way of purchase of assets. ([3])

(2) The business activities of the undertakings concerned are the following:

– Thermo Fisher is a global manufacturer and supplier of a broad range of analytical, research and bioprocessing products, and pharmaceutical contract development and manufacturing services,

– The Target provides purification and filtration technologies for use in the manufacturing of biopharmaceutical and medical technologies, microelectronics, food and beverage products.

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. The terminology of the TFEU will be used throughout this decision.
([2]) OJ L 1, 3.1.1994, p. 3 (the 'EEA Agreement').
([3]) OJ C, C/2025/3463, 24.6.2025.

(3) After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraph 5(d) of the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004. ([4])

(4) For the reasons set out in the Notice on a simplified treatment, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.

For the Commission

(Signed)
Olivier GUERSENT
Director-General
Directorate-General for Competition

([4]) OJ C 160, 5.5.2023, p. 1 (the 'Notice on a simplified treatment').